William Blair Investment Management LLC decreased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 100,460 shares of the pharmaceutical company’s stock after selling 1,944 shares during the period. William Blair Investment Management LLC’s holdings in GlaxoSmithKline PLC were worth $4,332,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GSK. FMR LLC raised its stake in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares during the last quarter. Thrivent Financial For Lutherans raised its stake in GlaxoSmithKline PLC by 87,023.5% in the first quarter. Thrivent Financial For Lutherans now owns 1,373,066 shares of the pharmaceutical company’s stock worth $57,884,000 after buying an additional 1,371,490 shares during the last quarter. Renaissance Technologies LLC raised its stake in GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares during the last quarter. Bank of America Corp DE raised its stake in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares during the last quarter. Finally, Marshall Wace North America L.P. raised its stake in GlaxoSmithKline PLC by 148.0% in the second quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock worth $48,138,000 after buying an additional 668,088 shares during the last quarter. Institutional investors and hedge funds own 8.99% of the company’s stock.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 39.47 on Friday. The company has a market cap of $96.46 billion, a price-to-earnings ratio of 38.77 and a beta of 1.03. The firm’s 50-day moving average price is $40.70 and its 200 day moving average price is $41.84. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, analysts predict that GlaxoSmithKline PLC will post $2.84 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.98%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is 197.00%.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/27/william-blair-investment-management-llc-sells-1944-shares-of-glaxosmithkline-plc-gsk.html.

A number of research firms have commented on GSK. BidaskClub raised GlaxoSmithKline PLC from a “strong sell” rating to a “sell” rating in a report on Friday. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday, July 27th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. Finally, Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.